Pre-clinical investigation of mesenchymal stromal cell-derived extracellular vesicles: a systematic review

The therapeutic potential of naturally secreted micro-and nanoscale extracellular vesicles (EVs) makes them attractive candidates for regenerative medicine and pharmaceutical science applications. To date, the results of numerous publications have shown the practicality of using EVs to replace mesenchymal stromal cells (MSCs) or liposomes. This article presents a systematic review of pre-clinical studies conducted over the past decade of MSC-derived EVs (MSC-EVs) used in animal models of disease. The authors searched the relevant literature in the PubMed and Scopus databases (9358 articles), and 690 articles met the inclusion criteria. The eligible articles were placed in the following disease categories: autoimmune, brain, cancer, eye, gastrointestinal, heart, inflammation/transplantation, liver, musculoskeletal, pancreas, spinal cord and peripheral nervous system, respiratory system, reproductive system, skin, urinary system and vascular-related diseases. Next, the eligible articles were assessed for the rate of publication and global distribution, methodology of EV isolation and characterization, route of MSC-EV administration, length of follow-up, source of MSCs and animal species. The current review classifies and critically discusses the technical aspects of these MSC-EV animal studies and discusses potential relationships between methodological details and the effectiveness of MSC-EVs as reported by these pre-clinical studies. Crown Copyright (c) 2021. Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy. All rights reserved.

Automated summary

This article reviews the use of MSC-derived EVs in animal disease models over the past decade. The study categorizes and critically discusses the technical aspects of these pre-clinical studies, exploring potential relationships between methodological details and the effectiveness of MSC-EVs.